Navigation Links
Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting
Date:7/28/2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data will be presented on RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV) at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC on October 25-28, 2008.

Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, will present pharmacokinetic and pharmacodynamic data from the Phase 2a proof-of-concept monotherapy study of RDEA806, during an oral presentation on October 26, 2008. Additionally, a poster will be presented on the resistance data for RDEA806 on the same day.

The presentation details are as follows:

Control Number: 4707

Title: Antiretroviral Therapy

Session Type: Slide Session

Presentation Title: RDEA806, a Novel HIV Non-Nucleoside Reverse

Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV

Patients

Session Day / Time: Sunday, October 26, 2008, 8:30am EDT

Presentation Time: 9:00am - 9:15am EDT

Location: Independence A (Grand Hyatt)

Control Number: 4643

Title: Antiretroviral Resistance and HIV Diagnostics

Session Type: Poster Session

Presentation Title: Resistance to RDEA806 Requires Multiple Mutations

Which Have Limited Cross-resistance to Other NNRTIs .

Session Day / Time: Sunday, October 26, 2008 11:15am EDT

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/23/2017)... Italy , May 23, 2017  Hunova, the first robotic gym ... trunk, has been officially launched in Genoa, Italy . ... Europe and the USA . The technology ... on the market by the IIT spin-off Movendo Technology thanks to a ... the Multimedia News Release, please click: ...
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
Breaking Biology News(10 mins):